TriSalus Life Sciences, Inc. (NASDAQ:TLSI – Get Free Report) Director Mats Wahlstrom bought 50,000 shares of TriSalus Life Sciences stock in a transaction dated Thursday, November 12th. The stock was acquired at an average cost of $2.24 per share, for a total transaction of $112,000.00. Following the completion of the acquisition, the director directly owned 197,555 shares in the company, valued at $442,523.20. This represents a 33.89% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
TriSalus Life Sciences Price Performance
NASDAQ TLSI opened at $2.27 on Tuesday. TriSalus Life Sciences, Inc. has a one year low of $2.16 and a one year high of $7.95. The stock’s 50 day simple moving average is $3.99 and its 200 day simple moving average is $4.28. The company has a debt-to-equity ratio of 47.60, a quick ratio of 4.97 and a current ratio of 4.22.
TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The company had revenue of $12.88 million during the quarter, compared to analysts’ expectations of $14.02 million. Sell-side analysts anticipate that TriSalus Life Sciences, Inc. will post -0.62 EPS for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. bought a new position in TriSalus Life Sciences in the 3rd quarter valued at $497,000. Empowered Funds LLC bought a new stake in shares of TriSalus Life Sciences during the third quarter worth $275,000. State Street Corp raised its position in shares of TriSalus Life Sciences by 9.5% during the third quarter. State Street Corp now owns 668,897 shares of the company’s stock worth $2,883,000 after acquiring an additional 57,934 shares during the last quarter. White Pine Capital LLC bought a new stake in shares of TriSalus Life Sciences during the third quarter worth $2,143,000. Finally, Royce & Associates LP acquired a new position in shares of TriSalus Life Sciences during the third quarter valued at $862,000. Institutional investors and hedge funds own 2.58% of the company’s stock.
Analyst Ratings Changes
A number of analysts have recently weighed in on the company. Guggenheim set a $12.00 target price on TriSalus Life Sciences in a research note on Wednesday, September 23rd. Wall Street Zen downgraded shares of TriSalus Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, November 7th. Citigroup reissued a “buy” rating on shares of TriSalus Life Sciences in a report on Tuesday, November 10th. Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Wednesday, November 4th. Finally, HC Wainwright lowered their price objective on shares of TriSalus Life Sciences from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, November 11th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, TriSalus Life Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.20.
Get Our Latest Analysis on TriSalus Life Sciences
About TriSalus Life Sciences
TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company’s TriNavĀ® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.
Recommended Stories
- Five stocks we like better than TriSalus Life Sciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
